Literature DB >> 29141812

Neuromyelitis optica spectrum disorders in Iran.

Sharareh Eskandarieh1, Saharnaz Nedjat2, Amir Reza Azimi3, Abdorreza Naser Moghadasi3, Mohammad Ali Sahraian4.   

Abstract

BACKGROUND: Neuromyelitys optica spectrum disorder (NMOSD) is a rare demyelinating disease; as a result, the epidemiological data on this disorder is scarce. In this regard, the aim of this study was to estimate the prevalence, serology, and clinical features of NMOSD in Caucasian population in Tehran, Iran.
METHOD: A cross sectional study was performed in Tehran from 2015 to 2016 among patients registered with NMOSD diagnosis, based on consensus criteria published in 2015. The researchers designed a questionnaire to cover the important epidemiological and clinical data of NMOSD in Tehran. Structured face to face interviews were conducted with 103 patients by trained interviewers to collect the data. The logistic regression was applied in analysis via SPSS software package. RESULT: The prevalence of NMOSD in Tehran was 0.86 per 100,000 in 2016. Female to male ratio was 5:1 with mean age at the disease onset of 31.54. NMO-IgG were positive in 44 (46.8%) patients, and the primary presenting symptoms of TM were observed in 29 (28.2%) patients. The adjusted odds ratio for sex was estimated for depression (OR = 6.83; 95% CI: 1.47, 31.71), migraine (OR = 1.27; 95% CI: 1.13, 1.42), and hypothyroidism (OR = 1.25; 95% CI: 1.12, 1.39).
CONCLUSION: The researchers indicated that the rate of NMOSD is significantly higher among females and younger age group. In addition, the history of depression, migraine, and hypothyroidism has been observed more among female patients in comparison to male patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical feature; Epidemiology; Neuromyelitis optica spectrum disorder; Prevalence

Mesh:

Substances:

Year:  2017        PMID: 29141812     DOI: 10.1016/j.msard.2017.10.007

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  10 in total

1.  The clinical profile of NMOSD in Australia and New Zealand.

Authors:  Wajih Bukhari; Laura Clarke; Cullen O'Gorman; Elham Khalilidehkordi; Simon Arnett; Kerri M Prain; Mark Woodhall; Roger Silvestrini; Christine S Bundell; Sudarshini Ramanathan; David Abernethy; Sandeep Bhuta; Stefan Blum; Mike Boggild; Karyn Boundy; Bruce J Brew; Wallace Brownlee; Helmut Butzkueven; William M Carroll; Celia Chen; Alan Coulthard; Russell C Dale; Chandi Das; Keith Dear; Marzena J Fabis-Pedrini; David Fulcher; David Gillis; Simon Hawke; Robert Heard; Andrew P D Henderson; Saman Heshmat; Suzanne Hodgkinson; Sofia Jimenez-Sanchez; Trevor J Kilpatrick; John King; Chris Kneebone; Andrew J Kornberg; Jeannette Lechner-Scott; Ming-Wei Lin; Christopher Lynch; Richard A L Macdonnell; Deborah F Mason; Pamela A McCombe; Jennifer Pereira; John D Pollard; Stephen W Reddel; Cameron Shaw; Judith Spies; James Stankovich; Ian Sutton; Steve Vucic; Michael Walsh; Richard C Wong; Eppie M Yiu; Michael H Barnett; Allan G Kermode; Mark P Marriott; John Parratt; Mark Slee; Bruce V Taylor; Ernest Willoughby; Robert J Wilson; Fabienne Brilot; Angela Vincent; Patrick Waters; Simon A Broadley
Journal:  J Neurol       Date:  2020-01-31       Impact factor: 4.849

2.  Letter to the Editor: Lack of Attention to Epidemiological Study of Neuromyelitis Optica Spectrum Disorder Compared with that of Multiple Sclerosis in Iran.

Authors:  Abdorreza Naser Moghadasi
Journal:  Int J MS Care       Date:  2019 Nov-Dec

3.  Increased Intracranial Pressure on a Patient with Neuromyelitis Optica Spectrum Disorder.

Authors:  Seyed Mohammad Forouzannia; Pourya Yarahmadi; Mohammad Alirezaei; Nasim Rezaeimanesh; Abdorreza Naser Moghadasi
Journal:  Caspian J Intern Med       Date:  2021

4.  Posterior Fossa Progressive Multifocal Leukoencephalopathy Secondary to Rituximab.

Authors:  Mounika Guduru; Venkata Sunil Bendi; Mariana S Bebawy; Dinesh Bande; Abhishek Matta
Journal:  Cureus       Date:  2020-10-10

5.  Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.

Authors:  Viktoria Papp; Zsolt Illes; Melinda Magyari; Nils Koch-Henriksen; Matthias Kant; Claudia Christina Pfleger; Shanu Faerch Roemer; Michael Broksgaard Jensen; Annett Evelyn Petersen; Helle Hvilsted Nielsen; Lene Rosendahl; Zsolt Mezei; Tove Christensen; Kristina Svendsen; Poul Erik Hyldgaard Jensen; Magnus Christian Lydolph; Niels Heegaard; Jette Lautrup Frederiksen; Finn Sellebjerg; Egon Stenager; Thor Petersen
Journal:  Neurology       Date:  2018-11-09       Impact factor: 9.910

6.  Association of cigarette smoking with neuromyelitis optica-immunoglobulin G sero-positivity in neuromyelitis optica spectrum disorder.

Authors:  Sharareh Eskandarieh; Abdorreza Naser Moghadasi; Mohammad Ali Sahraiain; Amir Reza Azimi; Negar Molazadeh
Journal:  Iran J Neurol       Date:  2019-07-06

7.  Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases.

Authors:  Maral Seyed Ahadi; Abdorreza Naser Moghadasi; Nasrin Asgari; Mohammad Ali Sahraian
Journal:  Caspian J Intern Med       Date:  2020

8.  Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review.

Authors:  Viktoria Papp; Melinda Magyari; Orhan Aktas; Thomas Berger; Simon A Broadley; Philippe Cabre; Anu Jacob; Jun-Ichi Kira; Maria Isabel Leite; Romain Marignier; Katsuichi Miyamoto; Jacqueline Palace; Albert Saiz; Maria Sepulveda; Olafur Sveinsson; Zsolt Illes
Journal:  Neurology       Date:  2020-12-11       Impact factor: 9.910

Review 9.  Update on neuromyelitis optica spectrum disorder.

Authors:  Kathryn B Holroyd; Giovanna S Manzano; Michael Levy
Journal:  Curr Opin Ophthalmol       Date:  2020-11       Impact factor: 4.299

10.  Incidence of neuromyelitis optica spectrum disorders in China: a large cohort study using claim data.

Authors:  Yiqun Wu; Mo Yang; Pei Gao; Zijing Wang; Junhui Wu; Jiating Wang; Quangang Xu; Huanfen Zhou; Tao Wu; Weiping Wu; Shihui Wei; Yong-Hua Hu
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.